

Branched Montbretin A mimics allow derivatisation and potent amylase inhibition.


Matthew Calvert¹, Ryan Sweeney¹, Hong-Ming Chen¹, Harbir Bajwa¹, Seyed A. Nasser¹, Davood Habibi² and Stephen G. Withers^{1*}

¹ Department of Chemistry,
University of British Columbia
2036 Main Mall
Vancouver, B.C.,
Canada V6T 1Z1

² Department of Organic Chemistry,
Faculty of Chemistry,
Bu-Ali Sina University,
Hamedan,
6517838683, Iran.


General Materials. All reagents and solvents were purchased from commercial suppliers (Sigma-Aldrich® or Thermo Fisher Scientific®) unless otherwise specified. Dichloromethane was dried by distillation with calcium hydride, tetrahydrofuran was distilled from sodium-benzophenone ketyl. Deionized water was prepared using a Millipore-Direct QTM 5 Ultrapure Water System. Analytical thin layer chromatography (TLC) was performed on Merck pre-coated 0.2 mm aluminum-backed sheets of Silica gel 60F254. TLC plates were visualized with UV light (254 nm) and stained with 1% ferric chloride in 50% water 50% methanol, or with 10% ammonium molybdate in 2 M H₂SO₄, followed by heating. Flash chromatography was performed with silica gel (pore size 60 Å, 220-440 mesh particle size) from Sigma-Aldrich. High performance liquid chromatography (HPLC) was performed on an Agilent 1260 Infinity Bio-inert Quaternary LC using an Agilent Eclipse XDB-C18 column (9.4 x 250 mm, 5 µm) at room temperature using acetonitrile and water with a flow rate of 4 mL/min. Elution of material was monitored by UV/Vis at 210, 280, and 350 nm. ¹H NMR, ¹³C NMR, HMBC, and HSQC spectra were acquired on a Bruker 300 MHz or 400 MHz spectrometer. Low resolution mass spectra were acquired on a Waters ZQ Mass Detector equipped with an ESCI ion source and Waters 2695 HPLC. High resolution mass spectra were acquired on a Waters/Micromass LCT ESI-TOF. Mass spectra for high molecular weight compounds (>2,000 Da) were acquired on a Bruker Autoflex MALDI-TOF instrument.

Perfluorophenyl (*S*)-2-(((benzyloxy)carbonyl)amino)-3-(4-(benzyloxy)phenyl)propanoate (**3**)




A solution of *N*-Cbz,*O*-Bn-tyrosine (1.013 g, 2.5 mmol) in DMF (5 mL) was treated with pyridine (0.22 mL), followed by pentafluorophenyl trifluoroacetate (0.5 mL, 0.82 g, 2.9 mmol). The reaction mixture was stirred at room temperature for 1 hour and was then diluted with ethyl acetate (100 mL) and washed with 0.1 M HCl and 5% NaHCO₃ (3 x 100 mL each). The organic layer was dried (Na₂SO₄), filtered and concentrated *in vacuo* to yield the *title compound* (1.26 g, 2.2 mmol, 88%) as a colourless solid. ¹H NMR (300 MHz, CDCl₃) δ 7.45-7.32 (m, 10 H, 10 x ArH), 7.12 (d, *J* = 8.6, 2 H, 2 x ArH), 6.93 (d, *J* = 8.6, 2 H, 2 x ArH), 5.19-5.12 (m, 3 H, NH + CH₂), 5.05 (s, 2 H, CH₂), 5.01-4.94 (m, 1 H, CH), 3.31-3.16 (m, 2 H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 168.3 (C=O), 158.5 (C=O), 155.7 (C), 137.0 (C), 136.0 (C), 130.5 (2 x CH), 128.74 (2 x CH), 128.70 (2 x CH), 128.5 (CH), 128.3 (2 x CH), 128.2 (CH), 127.6 (2 x CH), 126.8 (C), 115.4 (2 x CH), 70.2 (CH₂), 67.5 (CH₂), 54.8 (CH), 37.1 (CH₂). Pfp carbon signals not observed. HRMS (ESI-TOF): *m/z* calc'd for C₃₀H₂₂NO₅F₅Na: 594.1316 [M+Na]⁺; found: 594.1323.

Benzyl (*S*)-(3-(4-(benzyloxy)phenyl)-1-((2-hydroxyethyl)amino)-1-oxopropan-2-yl)carbamate (**4**)




A solution of **3** (960 mg, 1.68 mmol) in CH₂Cl₂ (10 mL) was treated with ethanolamine (205 mg, 203 μL, 3.36 mmol) dropwise. The reaction mixture was stirred for 1.5 hours and was then diluted with ethyl acetate (100 mL). The solution was then washed with 1 M HCl (2 x 100 mL), 1 M NaOH (2 x 100 mL), water (100 mL) and brine (100 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated *in vacuo* to yield the *title compound* (670 mg, 1.49 mmol, 89%) as a colourless solid. ¹H NMR (300 MHz, CDCl₃) δ 7.43-7.29 (m, 10 H, 10 x ArH), 7.10 (d, *J* = 8.5, 2 x H, 2 x ArH), 6.89 (d, *J* = 8.5, 2 x H, 2 x ArH), 6.23 (bt, *J* = 5.6, 1 H, NH), 5.45 (bd, *J* = 6.7, 1 H, NH), 5.06 (s, 2 H, CH₂), 5.02 (s, 2 H, CH₂), 4.33 (app q, *J* = 7.2, 1 H, CH), 3.60-3.47 (m, 2 H, CH₂), 3.28 (app q, *J* = 5.2, 2 H, CH₂), 3.07-2.92 (m, 2 H, CH₂). In agreement with the literature.¹

Benzyl (S)-1-((2-((7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yloxy)ethyl)amino)-3-(4-(benzyloxy)phenyl)-1-oxopropan-2-yl)carbamate (**8**)




A solution of flavonol **7** (240 mg, 0.42 mmol), alcohol **4** (190 mg, 0.42 mmol) and triphenylphosphine (550 mg, 2.1 mmol) in THF (15 mL) was cooled to 0 °C and treated dropwise with DIAD (0.2 mL, 1.0 mmol). The reaction mixture was stirred at 0 °C for 2.5 hours and was diluted with ethyl acetate and saturated aqueous NaHCO₃ (100 mL each). The aqueous layer was dried (Na₂SO₄), filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel (10 % - 20 % EtOAc in CH₂Cl₂), followed by a subsequent purification on silica gel (2:3 EtOAc:petroleum ether) gave the *title compound* (87mg, 87 μmol, 21%) as a yellow solid. ¹H NMR (300 MHz, CDCl₃) δ 7.97 (s, 1 H, OH), 7.65 (d, *J* = 1.9, 1 H, ArH), 7.61 (dd, *J* = 8.6, 1.9, 1 H, ArH), 7.51-7.26 (m, 25 H, 25 x ArH), 7.09 (d, *J* = 8.4, 2 H, 2 x ArH), 7.04 (d, *J* = 8.6, 1 H, 1 x ArH), 6.76 (d, *J* = 8.4, 2 H, 2 x ArH), 6.46 (d, *J* = 1.9, 1 H, ArH), 6.43 (d, *J* = 1.9, 1 H, ArH), 5.57 (d, *J* = 8.4, 1 H, NH), 5.27 (s, 2 H, CH₂), 5.24 (s, 2 H, CH₂), 5.20-5.08 (m, 4 H, 2 x CH₂), 4.82 (s, 2 H, CH₂), 4.52 (app q, *J* = 7.0, 1 H, CH), 3.71-3.58 (m, 2 H, CH₂), 3.38 (app q, *J* = 16.0, 2 H, CH₂), 3.15-2.99 (m, 2 H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 178.4 (C=O), 171.2 (C=O), 164.8 (C), 161.9 (C), 157.7 (C=O), 156.8 (C), 156.4 (C), 155.9 (C), 151.8 (C), 148.5 (C), 137.7 (C), 137.1 (C), 136.8 (C), 136.6 (C), 136.5 (C), 135.7 (C), 130.6 (2 x CH), 128.89 (C), 128.86 (2 x CH), 128.77 (2 x CH), 128.75 (2 x CH), 128.53 (4 x CH), 128.49 (2 x CH), 128.2 (CH), 128.13 (CH), 128.08 (CH), 128.03 (CH), 127.9 (CH), 127.5 (2 x CH), 127.32 (2 x CH), 127.30 (2 x CH), 127.2 (2 x CH), 122.84 (C), 122.80 (CH), 115.1 (CH), 114.8 (2 x CH), 113.9 (CH), 105.9 (C), 98.9 (CH), 93.3 (CH), 71.4 (CH₂), 71.3 (CH₂), 70.9 (CH₂), 70.6 (CH₂), 69.7 (CH₂), 66.9 (CH₂), 56.5 (CH), 40.3 (CH₂), 38.3 (CH₂). HRMS (ESI-TOF): *m/z* calc'd for C₆₂H₅₄N₂O₁₁Na: 1025.3625 [M+Na]⁺; found: 1025.3622.

(*S,E*)-3-(3,4-dihydroxyphenyl)-*N*-(1-((2-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)oxy)ethyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)acrylamide (**13**)




A solution of **8** (40 mg, 40 μ mol) in EtOH/THF (1:2, 9 mL) was treated with Pd/C (40 mg) and methanesulfonic acid (3 μ L, 46 μ mol). The flask was evacuated and placed under hydrogen pressure and stirred 16 h at room temperature. The reaction mixture was filtered through Celite, the filter cake was washed with ethanol (10 mL) and the filtrate treated with triethylamine (10 μ L, 72 μ mol). The filtrate was concentrated *in vacuo* and dissolved in DMF (1 mL). The reaction mixture was treated with pyridine (6.5 μ L, 80 μ mol), followed by **12** (13.8 mg, 40 μ mol). After stirring for 16 h, pyridine (6.5 μ L, 80 μ mol) was added and the reaction mixture was stirred for a further 5 h, whereupon further **12** was added (6.9 mg, 20 μ mol). After a total of 40 h stirring, the reaction mixture was quenched with water (100 μ L) and was concentrated *in vacuo*. Purification by flash chromatography on silica gel (78:10:10:2 to 67:15:15:3, CH₂Cl₂:MeOH:Acetone:Water) gave the *title compound* (10.3 mg, 15 μ mol, 38%) as a yellow solid. ¹H NMR (300 MHz, CD₃OD) δ 7.60 (d, *J* = 2.1, 1 H, ArH), 7.49 (dd, *J* = 8.6, 2.1, 1 H, ArH), 7.34 (d, *J* = 15.7, 1 H, CH), 7.07 (d, *J* = 8.5, 2 H, 2 x ArH), 6.98 (d, *J* = 1.8, 1 H, ArH), 6.91 (d, *J* = 8.6, 1 H, ArH), 6.88 (dd, *J* = 8.5, 1.8, 1 H, ArH), 6.73 (d, *J* = 8.5, 1 H, ArH), 6.64 (d, *J* = 8.5, 2 H, 2 x ArH), 6.43 (d, *J* = 15.7, 1 H, CH), 6.36 (d, *J* = 2.0, 1 H, ArH), 6.18 (d, *J* = 2.0, 1 H, ArH), 4.66 (dd, *J* = 8.3, 6.3, 1 H, CH), 4.00-3.79 (m, 2 H, CH₂), 3.49-3.44 (m, 2 H, CH₂), 3.13-2.85 (m, 2 H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 179.7 (C=O), 174.0 (C=O), 169.2 (C=O), 166.0 (C), 163.0 (C), 158.4 (C), 158.2 (C), 157.2 (C), 150.0 (C), 148.8 (C), 146.6 (C), 146.4 (C), 143.0 (CH), 138.3 (C), 131.3 (2 x CH), 129.2 (C), 128.2 (C), 122.8 (C), 122.4 (CH), 122.3 (CH), 117.9 (CH), 116.5 (2 x CH), 116.4 (CH), 116.2 (2 x CH), 115.3 (CH), 105.8 (C), 99.9 (CH), 94.8 (CH), 71.7 (CH₂), 57.1 (CH), 41.2 (CH₂), 38.3 (CH₂). HRMS (ESI-TOF): *m/z* calc'd for C₃₅H₃₀N₂O₁₂Na: 693.1696 [M+Na]⁺; found: 693.1691.

Benzyl (*S*)-3-(4-(benzyloxy)phenyl)-1-((3-hydroxypropyl)amino)-1-oxopropan-2-yl)carbamate (**6**)




A solution of **3** (850 mg, 1.5 mmol) in CH_2Cl_2 (10 mL) was treated with propanolamine (230 mg, 0.23 mL, 3.0 mmol) dropwise. The reaction mixture was stirred for 1.5 hours and was then diluted with ethyl acetate (100 mL). The solution was then washed with 1 M HCl (2 x 100 mL), 1 M NaOH (2 x 100 mL), water (100 mL) and brine (100 mL). The organic layer was dried (Na_2SO_4), filtered, and concentrated *in vacuo* to yield the *title compound* (620 mg, 1.3 mmol, 90 %) as a colourless solid. ^1H NMR (300 MHz, CDCl_3) δ 7.44-7.29 (m, 10 H, 10 x ArH), 7.10 (d, $J = 8.6$, 2 x H, 2 x ArH), 6.90 (d, $J = 8.6$, 2 x H, 2 x ArH), 6.08 (bt, $J = 5.5$, 1 H, NH), 5.30 (bs, 1 H, NH), 5.09 (s, 2 H, CH_2), 5.04 (s, 2 H, CH_2), 4.30 (app q, $J = 7.2$, 1 H, CH), 3.47 (t, $J = 5.5$, 2 H, CH_2), 3.31 (app q, $J = 6.1$, 2 H, CH_2), 3.10-2.92 (m, 2 H, CH_2), 2.24 (bs, 1 H, OH), 1.57 (p, $J = 5.7$, 2 H, CH_2). ^{13}C NMR (75 MHz, CDCl_3) δ 171.9 (C=O), 158.0 (C=O), 156.1 (C), 137.0 (C), 136.2 (C), 130.5 (2 x CH), 128.72 (2 x CH), 128.69 (2 x CH), 128.4 (CH), 128.2 (2 x CH), 128.1 (CH), 127.6 (2 x CH), 115.2 (2 x CH), 70.1 (CH_2), 67.2 (CH_2), 59.7 (CH_2), 56.8 (CH), 37.8 (CH_2), 36.7 (CH_2), 31.8 (CH_2). 1 x C obscured. HRMS (ESI-TOF): m/z calc'd for $\text{C}_{27}\text{H}_{30}\text{N}_2\text{O}_5\text{Na}$: 485.2047 [$\text{M}+\text{Na}$] $^+$; found: 485.2054.

Benzyl (*S*)-1-((3-((7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl)oxy)propyl)amino)-3-(4-(benzyloxy)phenyl)-1-oxopropan-2-yl)carbamate (**9**)




A solution of **7** (309 mg, 0.54 mmol), **5** (250 mg, 0.54 mmol) and triphenylphosphine (283 mg, 1.1 mmol) in THF (25 mL) was cooled to 0 °C and treated dropwise with DIAD (0.21 mL, 1.1 mmol). The reaction mixture was stirred at 0 °C for 2.5 hours and was diluted with ethyl acetate and saturated aqueous NaHCO₃ (100 mL each). The aqueous layer was dried (Na₂SO₄), filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel (2% MeOH in CH₂Cl₂) gave the *title compound* (188 mg, 0.16 mmol, 30 %) as a yellow solid. ¹H NMR (300 MHz, CDCl₃) δ 7.82 (bs, 1H, NH), 7.68 (s, 1H, ArH), 7.62 (d, *J* = 8.7, 1H, ArH), 7.50-7.17 (m, 24H), 7.11 (d, *J* = 8.6, 2H, 2 x ArH), 7.01 (d, *J* = 8.6, 2H, 2 x ArH), 6.76 (d, *J* = 8.3, 2H, 2 x H), 6.46 (bs, 2H, 2 x ArH), 5.61 (d, *J* = 8.3, 1H, NH), 5.26 (s, 2 H, CH₂), 5.21 (s, 2 H, CH₂), 5.13 (s, 2 H, CH₂), 5.12-5.02 (m, 2H, CH₂), 4.82 (s, 2 H, CH₂), 4.53 (app q, *J* = 7.1, 1 H, CH), 3.59-3.32 (m, 4H, 2 x CH₂), 3.16-2.96 (m, 2 H, CH₂), 1.64 (bs, 2 H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 178.7 (C=O), 171.0 (C=O), 164.8 (C), 161.9 (C), 157.7 (C=O), 156.7 (C), 156.3 (C), 155.8 (C), 151.7 (C), 148.5 (C), 137.7 (C), 137.1 (C), 136.9 (C), 136.5 (C), 135.7 (C), 130.6 (2 x CH), 129.04 (C), 128.85 (2 x CH), 128.73 (2 x CH), 128.70 (2 x CH), 128.5 (4 x CH), 128.4 (2 x CH), 128.2 (CH), 128.1 (CH), 128.04 (CH), 127.98 (CH), 127.9 (CH), 127.5 (2 x CH), 127.34 (2 x CH), 127.26 (4 x CH), 123.0 (C), 122.7 (CH), 114.9 (CH), 114.8 (2 x CH), 113.8 (CH), 106.0 (C), 98.9 (CH), 93.2 (CH), 71.6 (CH₂), 70.9 (CH₂), 70.6 (CH₂), 69.8 (CH₂), 69.1 (CH₂), 66.8 (CH₂), 56.6 (CH), 38.4 (CH₂), 35.7 (CH₂), 28.5 (CH₂). HRMS (ESI-TOF): *m/z* calc'd for C₆₃H₅₇N₂O₁₁: 1017.3957 [M+H]⁺; found: 1017.3963.

(*S,E*)-3-(3,4-dihydroxyphenyl)-*N*-(1-((3-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4*H*-chromen-3-yl)oxy)propyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)acrylamide (**1**)




A solution of **9** (46 mg, 0.045 mmol) in EtOH/THF (1:2, 9 mL) was treated with Pd/C (40 mg) and methanesulfonic acid (3 μ L, 46 μ mol). The flask was evacuated and placed under hydrogen pressure and stirred 16 h at room temperature. The reaction mixture was filtered through Celite, the filter cake was washed with ethanol (10 mL) and the filtrate treated with triethylamine (10 μ L, 72 μ mol). The filtrate was concentrated *in vacuo* and dissolved in DMF (1 mL). The reaction mixture was treated with pyridine (6.5 μ L, 80 μ mol), followed by **12** (13.8 mg, 40 μ mol). After stirring for 16 h, pyridine (6.5 μ L, 80 μ mol) was added and the reaction mixture was stirred for a further 5 h, whereupon further **12** was added (6.9 mg, 20 μ mol). After a total of 40 h stirring, the reaction mixture was quenched with water (100 μ L) and was concentrated *in vacuo*. Purification by flash chromatography on silica gel (78:10:10:2 to 67:15:15:3, DCM:MeOH:Acetone:Water) gave the *title compound* (11 mg, 0.016 mmol, 36 %) as a yellow solid. Analytical data as reported previously.²

Benzyl (*S*)-3-(4-(benzyloxy)phenyl)-1-((4-hydroxybutyl)amino)-1-oxopropan-2-yl)carbamate (**6**)




A solution of **3** (600 mg, 1.05 mmol) in dichloromethane (10 mL) was treated with butanolamine (187 mg, 0.19 mL, 2.1 mmol) dropwise. The reaction mixture was stirred for 1.5 hours and was then diluted with ethyl acetate (100 mL). The solution was then washed with 1 M HCl (2 x 100 mL), 1 M NaOH (2 x 100 mL), water (100 mL) and brine (100 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated in vacuo to yield the *title compound* (480 mg, 1.01 mmol, 96 %) as a colourless solid. ¹H NMR (300 MHz, CDCl₃) δ 7.44-7.29 (m, 10 H, 10 x ArH), 7.10 (d, *J* = 8.5, 2 x H, 2 x ArH), 6.89 (d, *J* = 8.5, 2 x H, 2 x ArH), 6.11 (bt, *J* = 5.3, 1 H, NH), 5.45 (bd, *J* = 6.5, 1 H, NH), 5.07 (s, 2 H, CH₂), 5.02 (s, 2 H, CH₂), 4.29 (app q, *J* = 7.2, 1 H, CH), 3.54 (t, *J* = 5.5, 2 H, CH₂), 3.18 (app q, *J* = 6.1, 2 H, CH₂), 3.07-2.91 (m, 2 H, CH₂), 1.89 (bs, 1 H, OH), 1.49-1.38 (m, 4 H, 2 x CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 171.0 (C=O), 158.0 (C=O), 156.0 (C), 137.0 (C), 136.3 (C), 130.5 (2 x CH), 128.9 (C), 128.73 (2 x CH), 128.69 (2 x CH), 128.4 (CH), 128.2 (2 x CH), 128.1 (CH), 127.6 (2 x CH), 115.2 (2 x CH), 70.2 (CH₂), 67.2 (CH₂), 62.4 (CH₂), 56.8 (CH), 39.4 (CH₂), 38.0 (CH₂), 29.7 (CH₂), 26.0 (CH₂). HRMS (ESI-TOF): *m/z* calc'd for C₂₈H₃₂N₂O₅: 477.2384 [M+H]⁺; found: 477.2387.

Benzyl (S)-1-((4-((7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl)oxy)butyl)amino)-3-(4-(benzyloxy)phenyl)-1-oxopropan-2-yl)carbamate (**10**)




A solution of **6** (250 mg, 0.525 mmol), **7** (300 mg, 0.525 mmol) and triphenylphosphine (206.56 mg, 0.7875 mmol) in THF (25 mL) was cooled to 0 °C and treated dropwise with DIAD (0.123 mL, 0.7875 mmol). The reaction mixture was stirred at 0 °C for 2.5 hours and was diluted with ethyl acetate and saturated aqueous NaHCO₃ (100 mL each). The aqueous layer was dried (Na₂SO₄), filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel (2% MeOH in CH₂Cl₂) gave the *title compound* (150 mg, 0.145 mmol, 28 %) as a yellow solid. ¹H NMR (300 MHz, CDCl₃) δ 7.67-7.61 (m, 2 H, 2 x ArH), 7.48-7.25 (m, 25 H, 25 x ArH), 7.07-7.00 (m, 3 H, 3 x ArH), 6.78 (d, *J* = 8.1, 2 H, 2 x ArH), 6.45 (bs, 3 H, 2 x ArH, 1 x NH), 5.50 (d, *J* = 6.9, 1 H, NH), 5.24 (s, 2 H, CH₂), 5.21 (s, 2 H, CH₂), 5.13 (s, 2 H, CH₂), 5.06 (s, 2 H, CH₂), 4.90 (s, 2 H, CH₂), 4.41 (app q, *J* = 7.0, 1 H, CH), 3.83-3.68 (m, 2 H, CH₂), 3.22 (bs, 2 H, CH₂), 3.06-2.91 (m, 2 H, CH₂). 1.54 (bs, 4 H, 2 x CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 178.9 (C=O), 171.0 (C=O), 164.7 (C), 162.1 (C), 157.8 (C=O), 156.8 (C), 156.2 (C), 151.6 (C), 148.4 (C), 138.3 (C), 137.04 (C), 136.99 (C), 136.6 (C), 136.4 (C), 135.9 (C), 130.5 (2 x CH), 128.9 (2 x CH), 128.77 (2 x CH), 128.74 (2 x CH), 128.6 (4 x CH), 128.5 (C), 128.2 (CH), 128.1 (3 x CH), 128.0 (CH), 127.6 (2 x CH), 127.5 (2 x CH), 127.4 (2 x CH), 127.3 (2 x CH), 123.3 (C), 123.0 (CH), 115.4 (CH), 114.9 (2 x CH), 113.8 (CH), 106.2 (C), 98.8 (CH), 93.2 (CH), 72.6 (CH₂), 71.7 (CH₂), 71.0 (CH₂), 70.6 (CH₂), 69.9 (CH₂), 67.0 (CH₂), 56.5 (CH), 39.3 (CH₂), 38.4 (CH₂), 27.9 (CH₂), 25.8 (CH₂). 1 x C not observed. HRMS (ESI-TOF): *m/z* calc'd for C₆₄H₅₈N₂O₁₁Na: 1053.3938 [M+Na]⁺; found: 1053.3925.

(*S,E*)-3-(3,4-dihydroxyphenyl)-*N*-(1-((4-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4*H*-chromen-3-yl)oxy)butyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)acrylamide (**14**)




A solution of **10** (40 mg, 40 μ mol) in EtOH/THF (1:2, 9 mL) was treated with Pd/C (40 mg) and methanesulfonic acid (3 μ L, 46 μ mol). The flask was evacuated and placed under hydrogen pressure and stirred 16 h at room temperature. The reaction mixture was filtered through Celite, the filter cake was washed with ethanol (10 mL) and the filtrate treated with triethylamine (10 μ L, 72 μ mol). The filtrate was concentrated *in vacuo* and dissolved in DMF (1 mL). The reaction mixture was treated with pyridine (6.5 μ L, 80 μ mol), followed by **12** (13.8 mg, 40 μ mol). After stirring for 16 h, pyridine (6.5 μ L, 80 μ mol) was added and the reaction mixture was stirred for a further 5 h, whereupon further caffeate-Pfp ester was added (6.9 mg, 20 μ mol). After a total of 40 h stirring, the reaction mixture was quenched with water (100 μ L) and was concentrated *in vacuo*. Purification by flash chromatography on silica gel (78:10:10:2 to 67:15:15:3, CH₂Cl₂:MeOH:Acetone:Water) gave the *title compound* (11 mg, 16 μ mol, 42%) as a yellow solid. ¹H NMR (300 MHz, CD₃OD) δ 7.57 (d, *J* = 2.0, 1 H, ArH), 7.47 (dd, *J* = 8.5, 2.1, 1 H, ArH), 7.34 (d, *J* = 15.6, 1 H, CH), 7.05 (d, *J* = 8.5, 2 H, 2 x ArH), 6.97 (d, *J* = 1.7, 1 H, ArH), 6.91-6.85 (m, 2 H, 2 x ArH), 6.73 (d, *J* = 8.1, 1 H, ArH), 6.67 (d, *J* = 8.5, 2 H, 2 x ArH), 6.42-6.36 (m, 2 H, 2 x ArH), 6.19 (d, *J* = 2.0, 1 H, ArH), 4.61 (t, *J* = 7.4, 1 H, CH), 3.85 (t, *J* = 5.4, 2 H, CH₂), 3.25-3.06 (m, 2 H, CH₂), 3.04-2.83 (m, 2 H, CH₂), 1.66-1.51 (m, 4 H, 2 x CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 180.1 (C=O), 173.7 (C=O), 168.9 (C=O), 165.8 (C), 163.1 (C), 158.4 (C), 158.3 (C), 157.2 (C), 149.8 (C), 148.8 (C), 146.7 (C), 146.3 (C), 142.9 (CH), 138.6 (C), 131.3 (2 x CH), 129.0 (C), 128.2 (C), 123.1 (C), 122.5 (CH), 122.2 (CH), 117.9 (CH), 116.7 (CH), 116.4 (CH), 116.3 (CH), 116.2 (2 x CH), 115.1 (CH), 105.9 (C), 99.7 (CH), 94.7 (CH), 73.4 (CH₂), 56.8 (CH), 40.0 (CH₂), 38.6 (CH₂), 28.8 (CH₂), 26.7 (CH₂). HRMS (ESI-TOF): *m/z* calc'd for C₃₇H₃₅N₂O₁₂: 699.2190 [M+H]⁺; found: 699.2191.

Benzyl (2*S*,3*S*)-3-(4-(benzyloxy)phenyl)-2-(quinolin-8-ylcarbamoyl)pyrrolidine-1-carboxylate (**19**)




A reaction vessel was charged with proline **18** (375 mg, 1.0 mmol), AgOAc (300 mg, 1.8 mmol), 4-benzyloxyphenyl iodide (558 mg, 1.8 mmol) and Pd(OAc)₂ (11 mg, 0.05 mmol). The reaction vessel was evacuated and back-filled with argon, then was sealed and stirred at 110 °C for 22 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (10 mL), filtered through celite, and further washed with ethyl acetate (2 x 10 mL). The filtrate was concentrated *in vacuo*, and the crude residue was purified by flash chromatography on silica gel (18% EtOAc in toluene) to give the *title compound* (329 mg, 0.59 mmol, 59 %) as a colourless solid. ¹H NMR (300 MHz, CDCl₃) δ 9.56 (s, 1H, NH), 8.63 (d, *J* = 4.5, 1 H), 8.61-8.55 (m, 1 H), 8.02 (dd, *J* = 15.2, 8.3, 1 H), 7.45-7.18 (m, 13 H), 7.02-6.90 (m, 2 H), 6.72-6.67 (m, 2 H), 5.30-5.09 (m, 2 H, CH₂), 4.79-4.57 (m, 3 H, CH₂ + CH), 4.19-4.06 (1 H, CH of CH₂), 3.78-3.60 (m, 2 H, CH + CH of CH₂), 2.86-2.67 (m, 1 H, CH of CH₂), 2.22-2.14 (p, *J* = 6.1, 1 H, CH of CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 168.7 (C=O), 157.9 (C), 154.9 + 154.4 (C=O), 147.9 (CH), 138.1 (C), 136.7 (C), 136.3 (C), 135.9 (CH), 133.7 (C), 128.9 (2 x CH), 128.7 (CH), 128.3 (2 x CH), 127.9 (CH), 127.7 (2 x CH), 127.5 (2 x CH), 127.2 (2 x CH), 127.0 (CH), 121.4 (CH), 121.3 (CH), 116.2 (CH), 114.7 (2 x CH), 69.6 (CH₂), 67.0 (CH₂), 66.5 + 66.3 (CH), 48.0 + 47.1 (CH), 46.6 + 46.2 (CH₂), 28.6 + 27.9 (CH₂). 2 x C not observed. HRMS (ESI-TOF): *m/z* calc'd for C₃₅H₃₂N₃O₄: 558.2393 [M+H]⁺; found: 558.2398.

Benzyl (2*S*,3*S*)-3-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)(quinolin-8-yl)carbamoyl)pyrrolidine-1-carboxylate (**20**)




A reaction vessel was charged with proline **19** (112 mg, 0.2 mmol), Boc_2O (436 mg, 2.0 mmol) and DMAP (50 mg, 0.4 mmol), and acetonitrile (0.4 mL) was added. The reaction vessel was evacuated briefly and backfilled with argon, and was then sealed and stirred at 55 °C. Further addition of Boc_2O (3 x 200 mg) was carried out after 1.5, 22, and 26 hours, and the temperature was increased to 70 °C after 22 hours. After 44 hours the reaction mixture was cooled to rt, diluted with sat aq ammonium chloride (2 mL) and CH_2Cl_2 (2 mL). The layers were separated and the aqueous was further extracted with CH_2Cl_2 (3 x 10 mL). The combined organics were dried (Na_2SO_4), filtered, and concentrated *in vacuo*. The residue was purified by flash chromatography on silica gel (20% ethyl acetate in toluene) to yield the *title compound* mixed with starting material **19**, which was used in the next step without further purification. HRMS (ESI-TOF): m/z calc'd for $\text{C}_{40}\text{H}_{40}\text{N}_3\text{O}_6$: 658.2917 $[\text{M}+\text{H}]^+$; found: 658.2915.

(2*S*,3*S*)-1-((benzyloxy)carbonyl)-3-(4-(benzyloxy)phenyl)pyrrolidine-2-carboxylic acid (**21**)




A solution of H_2O_2 (306 μL , 3.0 mmol, 30% in water) in THF (3 mL) was added to a solution of $\text{LiOH}\cdot\text{H}_2\text{O}$ (84 mg, 2.0 mmol) in H_2O (3 mL) at 0 °C under argon. This solution was then added to the mixture of **19** and **20** in THF (4 mL) at 0 °C under argon. The resultant solution was stirred at room temperature for 44 hours, whereupon sodium thiosulfate (10 mL) and ethyl acetate (10 mL) were added, and the solution was acidified to pH = 2 with 1 M HCl. The layers were separated and the aqueous was further extracted with ethyl acetate (3 x 10 mL), and the pooled organics dried (Na_2SO_4), filtered and concentrated *in vacuo*. The crude product was purified by flash chromatography on silica gel (E = 5% methanol in dichloromethane) to yield the *title compound* (25.8 mg, 60 μmol , 30% over two steps). ^1H NMR (400 MHz, CDCl_3) δ 7.40-7.23 (m, 10H), 7.13 (dd, $J = 8.3, 5.4$ 2 H), 6.89 (d, $J = 8.4$, 2 H), 5.14, 5.08 (ABq, 2H, $J_{\text{AB}} = 12.6$), 4.98 (s, 2H), 4.52 (app dd, $J = 8.7, 4.9$), 3.87 (app t, $J = 9.5$), 3.68-3.57 (m, 1H), 3.54-3.46 (m, 1H), 2.59-2.43 (m, 1H), 2.14-2.06 (m, 1H) ^{13}C NMR (100 MHz, CDCl_3) δ 175.6 + 175.2 (C=O), 158.34 + 158.30 (C), 155.1 + 154.4 (C=O), 137.1 + 137.0 (C), 136.6 + 136.4 (C), 129.1 + 129.0 (2 x CH), 128.7 (2 x CH), 128.6 + 128.5 (2 x CH), 128.5 + 128.3 (C), 128.2 + 128.0 (3 x CH), 127.7 (CH), 127.6 (2 x CH), 114.9 (2 x CH), 70.1 (CH_2), 67.4 + 67.3 (CH_2), 64.1 + 63.8 (CH), 47.5 + 46.5 (CH), 46.4 + 46.1 (CH_2), 28.7 + 27.7 (CH_2). HRMS (ESI-TOF): m/z calc'd for $\text{C}_{26}\text{H}_{25}\text{NO}_5\text{Na}$: 454.1625 $[\text{M}+\text{Na}]^+$; found: 454.1629.

Benzyl (2*S*,3*S*)-2-((3-((7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4*H*-chromen-3-yl)oxy)propyl)carbamoyl)-3-(4-(benzyloxy)phenyl)pyrrolidine-1-carboxylate (**23**)



A solution of **21** (25.8 mg, 60 μ mol) in DMF (0.2 mL) was treated with pyridine (5.3 μ L, 66 μ mol) and pentafluorophenyl trifluoroacetate (12 μ L, 70 μ mol). The reaction mixture was stirred at room temperature for 90 minutes, diluted with ethyl acetate (20 mL) and washed with 0.1 M HCl and 5% NaHCO₃ (3 x 20 mL each) and brine (20 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated *in vacuo*. The crude Pfp ester was then taken up in CH₂Cl₂ (1 mL) and was added to a solution of **22** (42 mg, 66 μ mol) and pyridine (10 μ L, 120 μ mol) in CH₂Cl₂ (1 mL). The reaction mixture was stirred at room temperature for three days, with further additions of amine (42 mg, t = 24h) and triethylamine (8.4 μ L, 60 μ mol, t = 43h and t = 66h). The reaction mixture was diluted with CH₂Cl₂ (10 mL) and was washed with 1 M HCl (3 x 5 mL) and brine (5 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated *in vacuo*. The crude residue was purified by flash chromatography on silica gel (20% to 40% ethyl acetate in toluene) to yield the *title compound* (36.4 mg, 35 μ mol, 58% over two steps) as a pale yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 12.51 (s) + 12.38 (s, 1 H), 7.68 (d, *J* = 3.1, 1H), 7.62 (d, *J* = 8.3, 1H), 7.49-7.17 (m, 27H), 7.00 (d, *J* = 8.7, 1H), 6.73 (app dd, *J* = 16.4, 8.3, 2H), 6.53-6.48 (m, 2H), 5.25-5.03 (m, 8H), 4.85-4.79 (m, 2H), 4.48 (app dd, *J* = 12.1, 8.5, 1H), 3.97 (app q, *J* = 9.0), 3.65-3.13 (m, 5H), 2.98-2.89 (m, 1H), 2.73 (app sept, *J* = 11.0, 1H), 2.08 (bs, 1H), 1.52-1.22 (m, 2H) ¹³C NMR (100 MHz, CDCl₃) δ 178.8 (C=O), 170.0 (C=O), 164.9 + 164.8 (C), 161.99 + 161.95 (C), 158.0 (C=O), 156.8 (C), 156.3 (C), 154.9 + 154.6 (C), 151.73 + 151.65 (C), 148.6 (C), 137.8 + 137.7 (C), 137.0 (C), 136.9 (C), 136.61 + 136.56 (C), 135.8 (C), 129.7 (2 x CH), 129.5 (CH), 128.9 (2 x CH), 128.8 (2 x CH), 128.7 (2 x CH), 128.54 (2 x CH), 128.48 (CH), 128.3 (CH), 128.2 (CH), 128.1 (CH), 128.0 (2 x CH), 127.64 (CH), 127.59 (2 x CH), 127.4 (2 x CH), 127.29 (2 x CH), 127.26 (2 x CH), 123.1 (C), 122.7 (CH), 115.0 (CH), 114.5 (2 x CH), 113.9 (CH), 106.1 (C), 99.0 (CH), 93.3 (CH), 71.63 + 71.59 (CH₂), 71.0 (CH₂), 70.6 (CH₂), 69.9 (CH₂), 68.4 + 68.3 (CH₂), 67.0 + 66.9 (CH₂), 65.7 + 65.4 (CH), 47.9 + 47.1 (CH), 46.7 + 46.3 (CH₂), 34.8 + 34.6 (CH₂), 29.0 + 28.4 + 28.1 (2 x CH₂). HRMS (ESI-TOF): *m/z* calc'd for C₆₅H₅₉N₂O₁₁: 1043.4113 [M+H]⁺; found: 1043.4128.

(2*S*,3*S*)-*N*-(3-((2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4*H*-chromen-3-yl)oxy)propyl)-1-((*E*)-3-(3,4-dihydroxyphenyl)acryloyl)-3-(4-hydroxyphenyl)pyrrolidine-2-carboxamide (**17**)




A solution of **23** (36 mg, 35 μ mol) in DMF (1 mL) was treated with a solution of PfpOH (32 mg, 0.17 mmol) in DMF (1 mL) and Pd/Al₂O₃ (10 mg), placed under hydrogen pressure and stirred for 18 hours at room temperature. The reaction mixture was filtered through celite and the filter cake washed with DMF (0.5 mL). The filtrate was cooled to 0 °C and was treated with Et₃N (10 μ L, 70 μ mol) and **12** (24 mg, 70 μ mol). The reaction mixture was then stirred at room temperature for 4 hours, cooled to 0 °C and diluted with HCl (0.1 M, 5 mL) and EtOAc (5 mL). The layers were separated and the organic layer was further washed with HCl (0.1 M, 3 x 5 mL) and brine (5 mL), and the pooled aqueous layers were extracted with EtOAc (5 mL). The combined organic layers were dried (Na₂SO₄), filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel (79:10:10:1 CH₂Cl₂:MeOH:Acetone:Water + 0.1% formic acid) gave the *title compound* (18.3 mg, 26 μ mol, 75%) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.59 + 7.54 (2 x d, *J* = 2.1, 1H), 7.46 + 7.45 (2 x dd, *J* = 8.4, 2.1, 1H), 7.39 + 7.38 (2 x d, *J* = 15.3, 1H), 7.12 + 7.09 (2 x d, *J* = 8.5, 1H), 6.97-6.82 (m, 3H), 6.74-6.47 (m, 4H), 6.40 + 6.33 (2 x d, *J* = 2.0, 1H), 6.23 + 6.22 (2 x d, *J* = 2.0, 1H), 4.75 + 4.66 (2 x d, *J* = 8.5, 1H), 4.12 (t, *J* = 9.0) + 4.03 (dd, *J* = 11.7, 9.0, 1H), 3.79-3.53 (m, 3H), 3.29-3.11 (m, 2H), 2.75-2.56 (m, 1H), 2.16 + 2.08 (2 x p, *J* = 6.0, 1H), 1.70-1.43 (m, 2H) ¹³C NMR (100 MHz, CDCl₃) δ 180.1, 172.3, 167.8, 165.9, 162.9, 158.4, 158.3, 157.8, 149.9, 149.1, 146.6, 146.4, 138.5, 130.6, 128.8, 128.2, 122.9, 122.5, 122.3, 116.6, 116.5, 116.4, 116.2, 116.1, 115.6, 115.3, 115.2, 105.9, 99.8, 94.9, 70.5, 66.8, 48.0, 47.5, 36.9, 30.3, 29.8. HRMS (ESI-TOF): *m/z* calc'd for C₃₈H₃₄N₂O₁₂: 711.2185 [M+H]⁺; found: 711.2188

(*R*)-3-(3-azido-2-hydroxypropoxy)-5,7-bis(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4H-chromen-4-one (**26a**)

OR


(*S*)-3-(3-azido-2-hydroxypropoxy)-5,7-bis(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4H-chromen-4-one (**26b**)



A solution of **24**³ (520 mg, 0.78 mmol), *R*-glycidol (78 μ L, 1.2 mmol) and triphenylphosphine (310 mg, 1.2 mmol) in THF (15 mL) was cooled to 0 °C and treated dropwise with DIAD (0.24 mL, 1.2 mmol). The reaction mixture was stirred at 0 °C for 16 hours and was diluted with ethyl acetate and saturated aqueous NaHCO₃ (40 mL each). The aqueous layer was dried (Na₂SO₄), filtered, and concentrated *in vacuo*. The crude product was triturated with methanol (8.0 mL), filtered, and washed with methanol (5.0 mL) and dried under vacuum to provide intermediate epoxide **25b** as a pink solid, which was used in the next step without further purification.

Epoxide **25b** was taken up in acetonitrile (17 mL) and was treated with lithium perchlorate (220 mg, 2.1 mmol) and sodium azide (130 mg, 2.1 mmol) and stirred at 90 °C. Upon completion (2 h), the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (20 mL). The combined organics were washed with water (20 mL) and brine (20 mL). The organic layer was dried (Na₂SO₄), filtered and concentrated *in vacuo*. The residue was purified by flash chromatography on silica gel (ethyl acetate/toluene 1:9) to provide *title compound* **26b** as a colourless solid (0.20 g, 0.26 mmol, 33%). ¹H NMR (300 MHz, CDCl₃) δ 7.71 (d, *J* = 2.0 Hz, 1H, ArH), 7.64 (dd, *J* = 8.6, 2.0 Hz, 1H, ArH), 7.58 (d, *J* = 7.5, 2H, 2 x ArH), 7.50-7.30 (m, 18H, 18 x ArH), 7.05 (d, *J* = 8.6 Hz, 1 H, ArH), 6.54 (d, *J* = 2.1 Hz, 1 H, ArH), 6.48 (d, *J* = 2.1 Hz, 1 H, ArH), 6.03 (d, *J* = 3.2, 1 H, OH), 5.26 (s, 4H, 2 x CH₂), 5.23 (s, 2H, CH₂), 5.10 (s, 2H, CH₂), 4.01-3.94 (m, 1H, CH), 3.83 (d, *J* = 4.5, 2H, CH₂), 3.44-3.33 (m, 2H, CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 174.7 (C=O), 163.4 (C), 159.9 (C), 158.9 (C), 153.8 (C), 151.3 (C), 148.7 (C), 140.1 (C), 137.1 (C), 136.7 (C), 136.2 (C), 135.6 (C), 128.9 (2 x CH), 128.8 (4 x CH), 128.7 (2 x CH), 128.6 (CH), 128.2 (CH), 128.1 (CH), 127.9 (CH), 127.7 (2 x CH), 127.3 (4 x CH), 126.7 (2 x CH), 123.2 (C), 122.5 (CH), 114.9 (CH), 114.0 (CH), 109.5 (C), 98.4 (CH), 94.0 (CH), 75.3 (CH₂), 71.5 (CH₂), 71.02 (CH₂), 70.97 (CH₂), 70.7 (CH₂), 69.7 (CH), 53.0 (CH₂). HRMS (ESI-TOF): *m/z* calc'd for C₄₆H₃₉N₃O₈Na: 784.2635 [M+Na]⁺; found: 784.2637.

An equivalent reaction starting with *S*-glycidol provided **26a** in 50% yield, analytical data as above.




A solution of DMAP in pyridine (2 mg/mL) was added to a solution of alcohol (**26a** or **26b**, 1 μmol), followed by a solution of Mosher's acid chloride (10 μL). Stirred for 1 hour at room temperature, analysed by TLC (20 cm plate, 10% ethyl acetate in toluene, stained in 1% FeCl_3 in $\text{MeOH}/\text{H}_2\text{O}$ (1:1)).



(*R*)-3-(3-Azido-2-((5-chloropentyl)oxy)propoxy)-5,7-bis(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4H-chromen-4-one (**27a**)

OR


(*S*)-3-(3-Azido-2-((5-chloropentyl)oxy)propoxy)-5,7-bis(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4H-chromen-4-one (**27b**)



A solution of **26a** (360 mg, 0.47 mmol) in bromochloropentane (1.9 mL, 14 mmol) was treated with 50% NaOH (3.4 mL) and tetrabutylammonium bisulfate (48 mg, 0.14 mmol). The biphasic mixture was stirred vigorously at room temperature for 4 hours, and then was cooled to 0 °C and was treated with water (15 mL) and CH₂Cl₂ (30 mL). The layers were separated and the aqueous layer was further extracted with CH₂Cl₂ (3 x 20 mL). The combined organic extracts were washed with brine (30 mL), dried (MgSO₄), filtered and concentrated *in vacuo*. Purification by flash chromatography on silica gel (5% ethyl acetate in toluene) gave *title compound* **27a** (330 mg, 0.38 mmol, 81%) as a colourless solid. ¹H NMR (300 MHz, CDCl₃) δ 7.69-7.64 (m, 2H, 2 x ArH), 7.58 (d, *J* = 7.7, 2H, 2 x ArH), 7.51-7.28 (m, 18H, 18 x ArH), 7.03 (d, *J* = 8.5 Hz, 1 H, ArH), 6.52 (d, *J* = 2.2 Hz, 1 H, ArH), 6.45 (d, *J* = 2.2 Hz, 1 H, ArH), 5.26 (s, 6H, 3 x CH₂), 5.09 (s, 2H, CH₂), 4.13 (dd, *J* = 4.7, 10.3) + 4.03 (dd, *J* = 10.2, 5.4, 2 H, CH₂), 3.74 (app p, *J* = 4.9, 1 H, CH), 3.57-3.33 (m, 6 H, 3 x CH₂), 1.72 (p, *J* = 7.2, 2 H, CH₂), 1.58-1.37 (m, 4 H, 2 x CH₂). ¹³C NMR (75 MHz, CDCl₃) δ 173.6 (C=O), 162.9 (C), 159.9 (C), 158.8 (C), 152.8 (C), 151.1 (C), 148.6 (C), 140.2 (C), 137.2 (C), 136.8 (C), 136.5 (C), 135.8 (C), 128.9 (2 x CH), 128.7 (4 x CH), 128.7 (2 x CH), 128.6 (CH), 128.14 (CH), 128.06 (CH), 127.8 (CH), 127.7 (2 x CH), 127.5 (2 x CH), 127.3 (2 x CH), 126.8 (2 x CH), 123.7 (C), 122.8 (CH), 115.5 (CH), 114.0 (CH), 110.1 (C), 98.3 (CH), 94.0 (CH), 78.2 (CH), 71.7 (CH₂), 71.1 (2 x CH₂), 70.9 (CH₂), 70.6 (CH₂), 70.1 (CH₂), 52.3 (CH₂), 45.1 (CH₂), 32.6 (CH₂), 29.3 (CH₂), 23.5 (CH₂). HRMS (ESI-TOF): *m/z* calc'd for C₅₁H₄₉N₃O₈Cl: 866.3208 [M+H]⁺; found: 866.3209.


An equivalent reaction starting with **26b** provided **27b** in 91% yield, analytical data as above.

(*E*)-*N*-((*S*)-1-(((*R*)-2-((5-Chloropentyl)oxy)-3-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)oxy)propyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-3-(3,4-dihydroxyphenyl)acrylamide (**30a**)




A solution of azide (**27a**) (174 mg, 0.201 mmol) and tyrosine derivative **3** (116 mg, 0.203 mol) in DMF (11.6 mL) was treated with Lindlar catalyst (174 mg), placed under hydrogen pressure (1 atm) and stirred for 16 hours at room temperature. The reaction mixture was filtered through celite, and the celite washed with DMF (2.50 mL) to give a solution of amide **32a**. This solution was treated with 5% palladium on alumina (54.0 mg) and pentafluorophenol (148 mg, 0.803 mmol), placed under hydrogen pressure (1 atm) and stirred for 16 hours at room temperature. The reaction mixture was filtered through celite, and the celite washed with DMF (5.0 mL) to give a solution of amine **33a**. This solution was evacuated-backfilled with argon, cooled to 0 °C and treated with **12** (140 mg, 0.402 mmol) and triethylamine (56.8 μL, 0.402 mmol). The reaction mixture was stirred at room temperature for 48 hours at room temperature, cooled to 0 °C and diluted with ethyl acetate (80 mL) and 0.1 M HCl (30 mL). The layers were separated and the organic layer further washed with 0.1 M HCl (30 mL) and brine (30 mL). The pooled aqueous washes were back-extracted with ethyl acetate (30 mL) and the combined organics were dried (Na₂SO₄), filtered, and concentrated *in vacuo*. Purification by silica gel chromatography (79:10:10:1 CH₂Cl₂:Acetone:MeOH:H₂O + 0.1% HCOOH to 73:12.5:12.5:2 CH₂Cl₂:Acetone:MeOH:H₂O + 0.1% HCOOH) gave the *title compound* (65.0 mg, 0.081 mmol, 40%) as a yellow powder. ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, *J* = 2.1, 1H), 7.53 (dd, *J* = 8.6, 2.1, 1H), 7.31 (d, *J* = 15.6, 1H), 7.05 (d, *J* = 8.5, 2H), 6.92 (d, *J* = 1.8, 1H), 6.86 (d, *J* = 8.4, 1H), 6.79 (dd, *J* = 8.3, 1.8), 6.70 (d, *J* = 8.1, 1H), 6.57 (d, *J* = 8.5, 2H), 6.38 (d, *J* = 15.6, 1H), 6.30 (d, *J* = 1.7, 1H), 6.18 (d, *J* = 1.7, 1H), 4.71 (t, *J* = 7.5, 1H), 3.77-3.68 (m, 2H), 3.50 (t, *J* = 6.7, 2H), 3.44-3.37 (m, 3H), 3.24 (dd, *J* = 10.3, 2.2, 1H), 3.04 (dd, *J* = 13.6, 7.8, 1H), 2.91 (dd, *J* = 13.6, 7.5, 1H), 1.72 (p, *J* = 7.2, 2H), 1.57-1.50 (m, 2H), 1.45-1.37 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 179.6, 174.0, 169.0, 165.8, 162.7, 158.2, 158.0, 157.2, 149.9, 148.7, 146.5, 146.4, 143.0, 138.0, 131.4 (x2), 129.0, 128.0, 122.73, 122.69, 122.2, 117.7, 116.5, 116.4, 116.3, 116.2 (x2), 115.2, 105.8, 99.9, 94.8, 77.1, 70.5, 57.3, 45.7, 40.3, 38.4, 33.6, 30.1, 24.5. HRMS (ESI-TOF): *m/z* calc'd for C₄₁H₄₂ClN₂O₁₃: 805.2370 [M+H]⁺; found: 805.2371

(*E*)-*N*-((*S*)-1-(((*S*)-2-((5-Chloropentyl)oxy)-3-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)oxy)propyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-3-(3,4-dihydroxyphenyl)acrylamide (**30b**)




A solution of azide (**27b**) (96 mg, 0.11 mmol) and tyrosine derivative **3** (64 mg, 0.11 mol) in DMF (6.0 mL) was treated with Lindlar catalyst (96 mg), placed under hydrogen pressure (1 atm) and stirred for 16 hours at room temperature. The reaction mixture was filtered through celite, and the celite washed with DMF (2.5 mL) to give a solution of amide **32a**. This solution was treated with 5% palladium on alumina (30 mg) and pentafluorophenol (82 mg, 0.44 mmol), placed under hydrogen pressure (1 atm) and stirred for 4 hours at room temperature. The reaction mixture was filtered through celite, and the celite washed with DMF (2.5 mL) to give a solution of amine **33a**. This solution was evacuated-backfilled with argon, cooled to 0 °C and treated with **12** (77 mg, 0.22 mmol) and triethylamine (31 μL, 0.22 mmol). The reaction mixture was stirred at room temperature for 16 hours at room temperature, cooled to 0 °C and diluted with ethyl acetate (80 mL) and 0.1 M HCl (30 mL). The layers were separated and the organic layer further washed with 0.1 M HCl (30 mL) and brine (30 mL). The pooled aqueous washes were back-extracted with ethyl acetate (30 mL) and the combined organics were dried (Na₂SO₄), filtered, and concentrated *in vacuo*. Purification by silica gel chromatography (79:10:10:1 CH₂Cl₂:Acetone:MeOH:H₂O + 0.1% HCOOH to 73:12.5:12.5:2 CH₂Cl₂:Acetone:MeOH:H₂O + 0.1% HCOOH) gave the *title compound* (50 mg, 0.06 mmol, 56%) as a yellow powder. ¹H NMR (400 MHz, CDCl₃) δ 7.56 (bs, 1H), 7.52 (d, *J* = 8.3, 1H), 7.30 (d, *J* = 15.7, 1H), 7.08 (d, *J* = 8.3, 2H), 6.92 (bs, 1H), 6.85 (d, *J* = 8.4), 6.80 (d, *J* = 8.1, 1H), 6.71-6.66 (m, 3H), 6.37 (d, *J* = 15.7, 1H), 6.30 (bs, 1H), 6.16 (bs, 1H), 4.69 (t, *J* = 7.2, 1H), 3.85-3.78 (m, 2H), 3.55-3.45 (m, 5H) 3.39-3.35 (m, 2H), 3.09 (dd, *J* = 13.5, 6.5, 1H), 2.92 (dd, *J* = 13.5, 8.0, 1H), 1.68 (p, *J* = 7.1, 2H), 1.53-1.45 (m, 2H), 1.42-1.36 (m, 2H) ¹³C NMR (100 MHz, CDCl₃) δ 179.6, 174.1 + 174.0, 169.0, 165.7, 164.7, 162.8, 158.2, 157.9, 149.8, 148.7, 146.5, 146.3, 142.9, 138.1, 131.3 (x2), 129.1, 128.1, 122.8, 122.7, 122.2, 117.7, 116.6, 116.4 (x2), 116.3 (x2), 115.2, 105.8, 99.8, 94.8, 77.7, 71.8, 70.6, 57.2 + 57.1, 45.7, 40.7 + 40.6, 38.3, 33.6, 30.2, 24.5. HRMS (ESI-TOF): *m/z* calc'd for C₄₁H₄₂ClN₂O₁₃: 805.2370 [M+H]⁺; found: 805.2368.

(*E*)-*N*-((*S*)-1-(((*R*)-2-((5-Azidopentyl)oxy)-3-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)oxy)propyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-3-(3,4-dihydroxyphenyl)acrylamide (**34a**)




A solution of **30a** (40 mg, 50 μ mol) in DMF (0.5 mL) was treated with tetrabutylammonium azide (100 mg, 350 μ mol) and stirred at 60 $^{\circ}$ C for 21 hours. The reaction mixture was diluted with ethyl acetate (10 mL), washed with HCl (0.1 M, 3 x 5 mL) and brine (10 mL). The organic layer was dried (Na_2SO_4), filtered and concentrated *in vacuo*. Purification by flash chromatography on silica gel (79:10:10:1 CH_2Cl_2 :Acetone:MeOH:H₂O + 0.1% HCOOH) gave the *title compound* (26.5 mg, 33 μ mol, 65%). ¹H NMR (300 MHz, CDCl_3) δ 7.57 (d, J = 2.0, 1H), 7.54 (dd, J = 8.4, 2.1, 1H), 7.31 (d, J = 15.7, 1H), 7.05 (d, J = 8.4, 2H), 6.92 (d, J = 1.8, 1H), 6.87 (d, J = 8.4, 1H), 6.79 (dd, J = 8.3, 1.8, 1H), 6.70 (d, J = 8.2, 1H), 6.57 (d, J = 8.4, 2H), 6.38 (d, J = 15.7, 1H), 6.32 (d, J = 1.9, 1H), 6.19 (d, J = 1.9, 1H), 4.70 (t, J = 7.5, 1H), 3.76-3.68 (m, 2H), 3.45-3.33 (m, 4H), 3.28-3.21 (m, 3H), 3.04 (dd, J = 13.7, 7.6, 1H), 2.91 (dd, J = 13.7, 7.6, 1H), 1.61-1.50 (m, 4H), 1.41-1.33 (m, 2H). ¹³C NMR (75 MHz, CDCl_3) δ 179.7, 173.9, 169.0, 165.9, 162.8, 158.3, 158.1, 157.3, 149.9, 148.8, 146.5, 146.4, 143.0, 138.1, 131.4 (x2), 129.0, 128.1, 122.8, 122.7, 122.2, 117.7, 116.6, 116.4 (x2), 116.2 (x2), 115.2, 105.8, 99.9, 94.8, 77.2, 71.2, 70.5, 57.3, 52.4, 40.3, 38.4, 30.4, 29.7, 24.4. HRMS (ESI-TOF): m/z calc'd for $\text{C}_{41}\text{H}_{42}\text{N}_5\text{O}_{13}$: 812.2774 [M+H]⁺; found: 812.2771.

(*E*)-*N*-((*S*)-1-(((*S*)-2-((5-Azidopentyl)oxy)-3-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)oxy)propyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-3-(3,4-dihydroxyphenyl)acrylamide (**34b**)



A solution of **30b** (40 mg, 50 μmol) in DMF (0.5 mL) was treated with tetrabutylammonium azide (100 mg, 350 μmol) and stirred at 60 $^{\circ}\text{C}$ for 21 hours. The reaction mixture was diluted with ethyl acetate (10 mL), washed with HCl (0.1 M, 3 x 5 mL) and brine (10 mL). The organic layer was dried (Na_2SO_4), filtered and concentrated *in vacuo*. Purification by flash chromatography on silica gel (79:10:10:1 CH_2Cl_2 :Acetone:MeOH:H₂O + 0.1% HCOOH) gave the *title compound* (29.8 mg, 37 μmol , 73%). ¹H NMR (300 MHz, CDCl_3) δ 7.56 (bs, 1H), 7.52 (d, $J = 8.3$, 1H), 7.30 (d, $J = 15.7$, 1H), 7.08 (d, $J = 8.3$, 2H), 6.92 (bs, 1H), 6.85 (d, $J = 8.4$), 6.80 (d, $J = 8.1$, 1H), 6.71-6.66 (m, 3H), 6.37 (d, $J = 15.7$, 1H), 6.30 (bs, 1H), 6.16 (bs, 1H), 4.69 (t, $J = 7.2$, 1H), 3.85-3.78 (m, 2H), 3.55-3.45 (m, 5H), 3.39-3.35 (m, 2H), 3.09 (dd, $J = 13.5$, 6.5, 1H), 2.92 (dd, $J = 13.5$, 8.0, 1H), 1.68 (p, $J = 7.1$, 2H), 1.53-1.45 (m, 2H), 1.42-1.36 (m, 2H) ¹³C NMR (75 MHz, CDCl_3) δ 179.7, 174.0, 169.0, 165.8, 162.9, 158.3, 158.0, 157.2, 149.9, 148.8, 146.5, 146.3, 142.9, 138.2, 131.3 (x2), 129.2, 128.1, 122.8, 122.7, 122.2, 117.7, 116.6, 116.4 (x2), 116.3 (x2), 115.2, 105.8, 99.8, 94.8, 77.7, 71.9, 70.6, 57.1, 52.4, 40.6, 38.3, 30.5, 29.7, 24.3. HRMS (ESI-TOF): m/z calc'd for $\text{C}_{41}\text{H}_{42}\text{N}_5\text{O}_{13}$: 812.2774 $[\text{M}+\text{H}]^+$; found: 812.2761.

(*E*)-3-(3,4-dihydroxyphenyl)-*N*-((*S*)-1-(((*S*)-3-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)oxy)-2-((5-(4-((2-(methoxyPEG)acetamido)methyl)-1H-1,2,3-triazol-1-yl)pentyl)oxy)propyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)acrylamide (**36a**)



A suspension of **34a** (6.5 mg, 8 μmol), PEG-5000 alkyne **35**⁴ (20 mg, 4 μmol), and BTTES ligand (0.2 mg, 0.4 μmol) in CH₂Cl₂ (0.2 mL) and tBuOH (0.4 mL) treated with a solution of CuSO₄•5H₂O (0.1 mg, 0.4 μmol) in water (0.1 mL) and sodium ascorbate (0.86 mg, 4.8 μmol) in water (0.1 mL). Stirred at room temperature for 39 hours and concentrated *in vacuo*. The residue was diluted with CH₂Cl₂ (1 mL), filtered through celite and concentrated *in vacuo*. The residue was dissolved in DMF (0.5 mL), cooled to 0 °C and precipitated with Et₂O. The precipitate was collected by centrifugation and washed with ice-cold Et₂O (2 x 1 mL) to give a pale yellow solid (22.8 mg, 98% from **35**).




Figure 1: MALDI-TOF analysis of **35**





Figure 2: MALDI-TOF analysis of **36a**

(*E*)-3-(3,4-dihydroxyphenyl)-*N*-((*S*)-1-(((*S*)-3-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)oxy)-2-((5-(4-((2-(methoxyPEG)acetamido)methyl)-1H-1,2,3-triazol-1-yl)pentyl)oxy)propyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)acrylamide (**36b**)



A suspension of **34b** (6.5 mg, 8 μ mol), PEG-5000 alkyne **35** (20 mg, 4 μ mol), and BTTES ligand (0.2 mg, 0.4 μ mol) in CH_2Cl_2 (0.2 mL) and *t*BuOH (0.4 mL) treated with a solution of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.1 mg, 0.4 μ mol) in water (0.1 mL) and sodium ascorbate (0.86 mg, 4.8 μ mol) in water (0.1 mL). Stirred at room temperature for 19 hours and concentrated *in vacuo*. The residue was diluted with CH_2Cl_2 (1 mL), filtered through celite and concentrated *in vacuo*. The residue was dissolved in DMF (0.5 mL), cooled to 0 $^\circ\text{C}$ and precipitated with Et_2O . The precipitate was collected by centrifugation and washed with ice-cold Et_2O (2 x 1 mL) to give a pale yellow solid (18 mg, 77% from **35**).





Figure 3: MALDI-TOF analysis of **36b**

(*E*)-3-(3,4-dihydroxyphenyl)-*N*-(((*S*)-1-(((*S*)-3-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)oxy)-2-((5-(4-((2-(methoxyPEG)amino)methyl)-1H-1,2,3-triazol-1-yl)pentyl)oxy)propyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-1H-1,2,3-triazol-1-yl)-(2-*O*-methyl)- α -D-cycloheptoglucose (**38a**)



A suspension of β -CD alkyne **37** (23 mg, 19.6 μ mol), **34a** (16 mg, 19.7 μ mol), and BTES ligand (12 mg, 24.3 μ mol) in *t*-BuOH (4.8 mL) was treated with a solution of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (40 mg, 0.16 mmol) in water (1.2 mL) and sodium ascorbate (16 mg, 80 μ mol) in water (1.2 mL). The mixture was stirred for 6 days at room temperature. The solution was concentrated *in vacuo*, re-dissolved in H_2O (5.0 mL), and lyophilized. The solid was dissolved in MeOH (1.0 mL), filtered and washed with MeOH to remove the solids, and the filtrate was concentrated *in vacuo*. Purification by flash chromatography on silica gel (9:1, 5:1 & 3:1 $\text{CH}_3\text{CN}:\text{H}_2\text{O}$ with 1% HCOOH) gave the *title compound* (10.7 mg, 5.4 μ mol, 27%). ^{13}C NMR (151 MHz, d_6 -DMSO) δ 177.69, 171.64, 165.43, 163.92, 160.82, 156.33, 155.73, 155.52, 148.45, 147.10, 145.20, 144.98, 143.47, 139.73, 136.58, 129.99, 127.93, 126.25, 123.95, 121.16, 120.82, 120.51, 117.87, 115.64, 115.46, 115.35, 114.76, 113.93, 104.06, 101.86, 101.83, 101.57, 100.08, 98.53, 93.66, 81.96, 81.45, 81.34, 81.19, 79.32, 76.34, 72.87, 72.45, 72.11, 71.94, 71.67, 71.59, 71.14, 69.70, 68.74, 64.27, 59.76, 54.68, 49.35, 39.52, 39.38, 39.24, 39.10, 38.96, 38.82, 38.68, 36.86, 29.58, 28.90, 28.73, 28.59, 22.44, 22.03. MS (MALDI): m/z calc'd for $\text{C}_{86}\text{H}_{113}\text{N}_5\text{O}_{48}$: 2007.8 [$\text{M}+\text{Na}$] $^+$; found: 2007.8.





Figure 4: **38a** MALDI

(2-(polyethyleneglycolyl)azidoethyl)aminoethane **41**, & **42** (PEG600 {n = ~13} **42** as an example)



A solution of TsCl (3.33 g, 17.5 mmol) in CH_2Cl_2 (10 mL) was added slowly over 30 min to a mixture of pyridine (5 mL), PEG600 (2.1 g, 3.5 mmol) and DMAP (0.3 g) in CH_2Cl_2 (10 mL) at 0 °C. The mixture was stirred at 0 °C for 2 h, then gradually warmed to room temperature and stirred overnight. The reaction mixture was diluted with ethyl acetate (300 mL), washed with 1M HCl (2 x 100 mL), saturated NaHCO_3 (100 mL) and brine (100 mL). The organic layer was dried over MgSO_4 , filtered and concentrated. The resulting residual was purified by flash column chromatography on silica gel (50:1 and 25:1 DCM:MeOH) to afford the tosylated PEG as an oil (2.69 g, 2.96 mmol, 84%). The tosylated PEG was then dissolved in DMF (30 mL), and NaN_3 (0.87 g, 13.4 mmol) was added. The mixture was stirred overnight at 50 °C, before cooling to room temperature. The mixture was diluted with ethyl acetate (200 mL), washed with water (2 x 50 mL) and brine (50 mL). The aqueous phase was extracted with ethyl acetate (4 x 100 mL). The combined organic phase was dried over MgSO_4 , filtered and concentrated. The crude product was purified by flash column chromatography on silica gel (15:1 DCM:MeOH) gave the di-azido-PEG derivatives **40** (1.742 g, 2.68 mmol, 91%). To the di-azido-PEG derivatives **40** (1.742 g) in ether (3.5 mL)/THF (0.8 mL)/1M HCl (3.5 mL) with vigorously stirring at room temperature, was added PPh_3 (702 mg, 2.68 mmol) in Et_2O (16 mL) slowly dropwise over the course of 2.5 h. The mixture was then stirred for an additional 24 h at room temperature. Upon completion, water (20 mL) was added, and the two layers were separated. The aqueous layer was extracted with ether (3 x 10 mL). The aqueous phase was cooled with an ice bath, and solid NaOH was added until the pH was >12, extracted with DCM (3 x 30 mL). The organic phase was washed with brine (30 mL), dried over MgSO_4 , filtered and evaporated. The resulting residual was purified by flash column chromatography on silica gel (9:1 DCM:MeOH, with 1% v/v 1M NH_4OH) to afford the product **42** as an oil (597 mg, 0.96 mmol, 36%). ^1H NMR (400 MHz, CDCl_3) δ 7.84 (brs), 3.79 (t, J 4.88 Hz), 3.62 (brd, J 4.96 Hz), 3.55 (m), 3.28 (t, J 4.92 Hz), 3.09 (brd, J 4.60 Hz). ^{13}C NMR (100 MHz, CDCl_3) δ 70.69, 70.66, 70.63, 70.56, 70.51, 70.47, 70.45, 70.41, 70.39, 70.34, 70.21, 70.19, 70.13, 70.05, 70.00, 69.93, 66.81, 50.72, 40.28. Product **41** was obtained as a slightly yellow oil in 62% overall yield. ^1H NMR (400 MHz, CDCl_3) δ 3.68-3.62 (m, 12 H), 3.52 (t, 2 H, J 5.20 Hz), 3.39 (t, 2 H, J 5.04 Hz), 2.87 (t, 2 H, J 5.20 Hz), 1.74 (brs, 2 H). ^{13}C NMR (100 MHz, CDCl_3) δ 73.34, 70.67, 70.63, 70.26, 70.02, 50.66, 41.76. ESI-MS: m/z calc'd for $\text{C}_8\text{H}_{18}\text{N}_4\text{O}_3$: 219.1 [M+H]⁺; found: 219.2.





Figure 5: **42** ESI-MS

(*E*)-3-(3,4-dihydroxyphenyl)-*N*-((*S*)-1-(((*S*)-3-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)oxy)-2-((5-(4-((2-(polyethyleneglycolyl)amino)methyl)-1H-1,2,3-triazol-1-yl)pentyl)oxy)propyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-1H-1,2,3-triazol-1-yl-(2-*O*-methyl)- α -D-cycloheptoglucose (**47a**, **48a**, & **47a** used as an example)



A suspension of β -CD alkyne **37** (126 mg, 0.11 mmol), PEG-200 azide **41** (70 mg, 0.32 mmol), and BTTES ligand (73 mg, 0.15 mmol) in *t*-BuOH (10 mL) was treated with aqueous solutions of CuSO_4 (0.133 M, 7 mL) and sodium ascorbate (0.066 M, 7 mL), and the mixture was stirred for 24 h at room temperature. After evaporation, the resulting residue was purified by flash column chromatography on silica gel (4:1:1, $\text{CH}_3\text{CN}:\text{H}_2\text{O}:\text{NH}_4\text{OH}$), the fractions were combined and evaporated, redissolved in water and lyophilized to afford an off-white solid (**43**, 183 mg, not pure). The solid (117 mg) was dissolved in dry DMF (20 mL) under N_2 at room temperature, and then were added anhydrous K_2CO_3 (70 mg, 0.51 mmol), KI (2 mg, 12 μmol) and propargyl bromide (80% in toluene) (9 μL , 83.5 μmol), the reaction mixture was stirred for 24 h in the dark at room temperature under N_2 , filtered through Celite and concentrated. The resulting residues was purified by flash column chromatography on silica gel (5:1:1, 4.5:1:1, 4:1:1, $\text{CH}_3\text{CN}:\text{H}_2\text{O}:\text{NH}_4\text{OH}$) to give by-product, product (**45**, 21 mg) and starting material respectively. A suspension of **45** (12 mg, 8.4 μmol), **34a** (4.6 mg, 5.7 μmol) and BTTES (3.5 mg, 7.1 μmol) in *t*-BuOH (1.6 mL) was treated with $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.133 M, 0.41 mL) and sodium ascorbate (0.066 M, 0.41 mL), and the reaction mixture was stirred for 19 h at room temperature. The product was precipitated out on the wall of flask, solution was poured out and washed with MeOH. The precipitate was dissolved water, loaded on SepPak (C_{18}), eluted with water, MeOH and MeOH with 1% HCOOH. The fractions were combined and evaporated. The residue was redissolved in water and lyophilized to afford the desired product (**47a**, 5.7 mg, 2.5 μmol , 45%). Overall yield based on alkyne: **47a**, 15%; **48a**, 13%.




Figure 6: 43 MALDI




Figure 7: 44 MALDI




Figure 8: 45 MALDI




Figure 9: 46 MALDI




Figure 10: 47a MALDI





Figure 11: 48a MALDI

(E)-3-(3,4-dihydroxyphenyl)-N-((S)-1-(((R)-3-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)oxy)-2-((5-(5-(((2-(2-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)ethoxy)polyethyleneglycolyl)amino)methyl)-1H-1,2,3-triazol-1-yl)pentyl)oxy)propyl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)acrylamide **49a**



A suspension of **42** (80 mg, 0.13 mmol), propargyl alcohol (13 μ L, 0.22 mmol), and BTES ligand (6.5 mg, 13 μ mol) in *t*-BuOH (1.3 mL) and water (1.3 mL) was treated with $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.133 M, 0.3 mL) and sodium ascorbate (0.066 M, 0.3 mL), and the mixture was stirred for 36 h at room temperature. The reaction mixture was evaporated and co-evaporated with toluene three times, the resulting residue was purified by flash column chromatography on silica gel (6:1, DCM:MeOH, with 1% 1M NH_4OH) to afford **50** as an oil (82 mg, 0.12 mmol, 94%). A suspension of the solid (82 mg, 0.12 mmol), anhydrous K_2CO_3 (51 mg, 0.37 mmol), KI (2 mg, 12 μ mol) and propargyl bromide (80% in toluene) (13 μ L, 0.12 mmol) in dry DMF (6mL) was stirred overnight in the dark under N_2 at room temperature, and the reaction mixture was filtered through Celite and concentrated. The resulting residues were purified by flash column chromatography on silica gel (9:1 and 7:1, DCM:MeOH, with 1% 1M NH_4OH) to afford the product as a foam (**51**, 27 mg, 38.1 μ mol, 32%) (48% based on the consumed starting material, 29 mg of starting material was recovered). A suspension of **51** (7 mg, 9.9 μ mol), **34a** (6 mg, 7.4 μ mol) and BTES (5 mg, 10.1 μ mol) in *t*-BuOH (2.4 mL) was treated with $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.133 M, 0.6 mL) and sodium ascorbate (0.066 M, 0.6 mL), and the reaction mixture was stirred overnight at room temperature. The product was precipitated out on the wall of flask, solution was poured out and washed with MeOH and water respectively. The precipitate was dissolved in minimum amount of DMSO, and diluted with water, lyophilized to afford the product **49a** a yellow solid (5.91 mg, 3.9 μ mol, 53%).




Figure 12: **50** ESI-MS




Figure 13: 51 ESI-MS




Figure 14: 49a MALDI



NMR Data




Figure 4: ¹H NMR (3)




Figure 5: ¹³C NMR (3)

ubc_1H_CDCl3 (C:\Bruker\topspin2.1) swithers 7



```

Current Data Parameters
NAME      MBC055
EXPNO     1
PROCNO    1

F2 - Acquisition Parameters
Date_     20180321
Time      10.41
INSTRUM   spect
PROBHD    5 mm QNP 1H/1
PULPROG   zg30
TD         16466
SOLVENT   CDCl3
NS         16
DS         2
SWE        3742.515 Hz
FIDRES     0.227287 Hz
AQ          2.1998577 sec
RG          322.5
DM          133.600 usec
DE          6.00 usec
TE          297.9 K
D1          1.00000000 sec
TD0         1

===== CHANNEL f1 =====
NUC1       1H
P1         12.90 usec
PL1        0 dB
PL1W       15.07131863 W
SFO1       300.1318008 MHz

F2 - Processing parameters
SI         32768
SF         300.1300052 MHz
WDW         EM
SSB         0
LB         0.50 Hz
GB         0
PC         1.00
  
```




Figure 6: ¹H NMR (4)




Figure 7: ^{13}C NMR (4)




Figure 8: ¹H NMR (8)

ubc_1H MeOD (C:\Bruker\topspin2.1) swithers 20



Current Data Parameters
NAME MBCD91
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20180427
Time 12.34
INSTRUM spect
PROBHD 5 mm QNP 1H/1
PULPROG zgpg30
TD 16466
SOLVENT MeOD
NS 16
DS 2
SWH 3742.515 Hz
FIDRES 0.227287 Hz
AQ 2.1998577 sec
RG 322.5
DW 133.600 usec
DE 6.00 usec
TE 297.9 K
D1 1.00000000 sec
TDO 1

===== CHANNEL f1 =====
NUC1 1H
P1 12.90 usec
PL1 0 dB
PLW 15.07131863 W
SFO1 300.1318008 MHz

F2 - Processing parameters
SI 32768
SF 300.1300077 MHz
WDW EM
SSB 0
LB 0.50 Hz
GB 0
PC 1.00




Figure 10: ¹H NMR (13)



ubc_13C(1H) MeOD (C:\Bruker\topspin2.1) swithers 20

179.71
174.02
169.19
166.00
161.96
158.42
158.16
157.20
150.02
148.80
146.58
146.15
142.96
138.28
131.23
129.18
128.22
122.94
122.43
122.27
117.90
116.54
116.37
116.20
115.27
106.80
99.89
94.78
71.70
57.05
47.11
38.77
27.11

Current Data Parameters
 NAME MBC091
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20180427
 Time 15.44
 INSTRUM spect
 PROBHD 5 mm QNP 1H/1
 PULPROG zgpg30
 TD 27870
 SOLVENT MeOD
 NS 6000
 DS 4
 SWH 18832.393 Hz
 FIDRES 0.675723 Hz
 AQ 0.7399405 sec
 RG 16384
 DW 26.550 usec
 DE 37.93 usec
 TE 298.3 K
 D1 1.00000000 sec
 D11 0.03000000 sec
 TDO 1

CHANNEL f1
 NSC1 13C
 P1 11.25 usec
 PL1 -1.00 dB
 PL1W 47.43416595 W
 SFO1 75.4755490 MHz

CHANNEL f2
 CPDPRG2 waltz16
 NSC2 1H
 PCPD2 100.00 usec
 PL2 0 dB
 PL2 17.65 dB
 PL3 15.00 dB
 PL2W 15.07131863 W
 PL12W 0.25891146 W
 PL13W 0.18973666 W
 SFO2 300.1316000 MHz

F2 - Processing parameters
 SI 32768
 SF 75.4676441 MHz
 WDW EM
 SSB 0
 LB 0
 GB 0
 PC 2.00 Hz
 MC 1.00




Figure 11: ¹³C NMR (13)



ubc_1H_CDCl3 (C:\Bruker\topspin2.1) swithers 30



Current Data Parameters
NAME DHG
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20180718
Time_ 8.37
INSTRUM spect
PROBHD 5 mm QNP 1H/1
PULPROG zg30
TD 16466
SOLVENT CDCl3
NS 16
DS 2
SWE 3742.515 Hz
FIDRES 0.227287 Hz
AQ 2.1998577 sec
RG 645.1
DM 133.600 usec
DE 6.00 usec
TE 297.7 K
D1 1.00000000 sec
TD0 1

CHANNEL f1
NUC1 1H
P1 12.80 usec
PL 0 dB
PLW 15.07131863 W
SFO1 300.1318008 MHz

F2 - Processing parameters
SI 32768
SF 300.1300054 MHz
WDW EM
SSB 0
LB 0.50 Hz
GB 0
PC 1.00




Figure 12: ¹H NMR (6)



ubc_13c(1h) CDC13 (C:\Bruker\topspin2.1) swithers 1




Figure 13: ¹³C NMR (6)



Current Data Parameters
 NAME DELIMPUREZ4
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20180825
 Time_ 4.36
 INSTRUM spect
 PROBHD 5 mm QNP 1H/1
 PULPROG zg30
 TD 16466
 SOLVENT CDCl3
 NS 16
 DS 2
 SWE 3742.515 Hz
 FIDRES 0.227287 Hz
 AQ 2.1998577 sec
 RG 114
 DW 133.600 usec
 DE 6.00 usec
 TE 298.3 K
 D1 1.00000000 sec
 TDO 1

CHANNEL f1
 NUC1 1H
 P1 12.80 usec
 PL1 0 dB
 PL1W 15.07131863 W
 SFO1 300.1318008 MHz

F2 - Processing parameters
 SI 32768
 SF 300.1300069 MHz
 WDW EM
 SSB 0
 LB 0.50 Hz
 GB 0
 PC 1.00

ubc_1H_CDCl3 (C:\Bruker\topspin2.1) swithers 3




Figure 14: ¹H NMR (9)




Figure 16: ¹H NMR (6)




Figure 17: ¹³C NMR (6)




Figure 18: ¹H NMR (10)



ubc_13c[1H] CDCl3 (C:\Bruker\topspin2.1) swithers 31

178.94
171.02
164.67
162.10
157.84
156.77
156.18
151.59
148.45
138.27
137.04
136.99
136.63
136.40
135.86
130.54
128.89
128.77
128.74
128.60
128.53
128.12
127.99
127.60
127.49
127.41
127.33
123.33
123.02
118.39
114.59
112.82
108.23
98.81
93.22
72.55
70.98
70.66
71.65
69.94
69.94
67.67
60.00
56.51
38.39
27.96
25.89

```

Current Data Parameters
NAME_          DMR
EXPNO          2
PROCNO         1

F2 - Acquisition Parameters
Date_          20180718
Time           17.45
INSTRUM       spect
PROBHD        5 mm QNP 1H/1
PULPROG       zgpg30
TD             27870
SOLVENT       CDCl3
NS             2000
DS             4
SWH           18832.393 Hz
FIDRES        0.67573 Hz
AQ            0.7395405 sec
RG            16384
DQ            26.550 usec
DE            37.93 usec
TE            297.7 K
D1            1.00000000 sec
D11           0.03000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          13C
P1            9.95 usec
PL1           -1.00 dB
PL1W          47.43416595 W
SFO1          75.4755490 MHz

===== CHANNEL f2 =====
CPDPRG2       waltz16
NUC2          1H
PCPD2         100.00 usec
RG2           0 dB
PL2           17.06 dB
PL3           19.00 dB
PLZ          15.07131863 W
PL2W          0.24668980 W
PL1W          0.18973666 W
SFO2          300.1316000 MHz

F2 - Processing parameters
SI            32768
SF            75.4677401 MHz
WDW           EM
SSB           0
GB            0
PC            2.00 Hz
=====
  
```




Figure 19: ¹³C NMR (10)

ubc_1H MeOD (C:\Bruker\topspin2.1) swithers 2



```

Current Data Parameters
NAME          DHK9B
EXPNO         1
PROCNO        1

F2 - Acquisition Parameters
Date_         20180810
Time          4.59
INSTRUM       spect
PROBHD        5 mm QNP 1H/1
PULPROG       zg30
TD            16466
SOLVENT       MeOD
NS            16
DS            2
SWH           3742.515 Hz
FIDRES        0.227287 Hz
AQ            2.1998577 sec
RG            256
DM            133.600 usec
DE            6.00 usec
TE            297.7 K
D1            1.0000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          1H
P1            12.80 usec
PL1           0 dB
PL1M          15.07131863 W
SFO1          300.1318008 MHz

F2 - Processing parameters
SI            32768
SF            300.1300077 MHz
WDW           EM
SSB           0
LB            0.50 Hz
GB            0
PC            1.00
  
```





Figure 20: ¹H NMR (14)



ubc_13C[1H] MeOD (C:\Bruker\topspin2.1) swithers 2

180.08
173.68
168.91
165.94
163.09
158.43
158.35
157.26
149.91
146.94
146.66
146.30
147.68
138.63
131.32
129.05
128.21
123.09
122.68
122.25
117.90
116.72
116.41
116.35
116.22
106.93
99.72
94.69
73.41
56.81
40.00
38.59
28.24
28.70

Current Data Parameters
NAME DHEK98
EXPRO 2
PROCNO 1

F2 - Acquisition Parameters
Date_ 20180810
Time 17.04
INSTRUM spect
PROBHD 5 mm QNP 1H/1
PULPROG zgpg30
TD 27870
SOLVENT MeOD
NS 2000
DS 4
SWH 18832.393 Hz
FIDRES 0.67573 Hz
AQ 0.7395405 sec
RG 16384
DQ 26.550 usec
DE 31.93 usec
TE 297.7 K
D1 1.00000000 sec
D11 0.03000000 sec
TD0 1

CHANNEL f1
NUC1 13C
P1 9.95 usec
PL1 -1.00 dB
PL1W 47.43416595 W
SFO1 75.4755490 MHz

CHANNEL f2
CPDPRG2 waltz16
NUC2 1H
PCPD2 100.00 usec
PL2 0 dB
PL3 17.06 dB
PL13 16.00 dB
PL2W 15.07131863 W
PL12W 0.24668980 W
PL13W 0.18973666 W
SFO2 300.1316000 MHz

F2 - Processing parameters
SI 32768
SF 75.4676440 MHz
WDW EM
SSB 0
GB 0
CB 0
PC 2.00 Hz
MC 1.00




Figure 21: ¹³C NMR (14)

ubc_1H_CDCl3 (C:\Bruker\topspin2.1) swithers 17



Current Data Parameters
NAME MDC279-20190529
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20190530
Time 9.00
INSTRUM spect
PROBHD 5 mm QNP 1H/1
PULPROG zg30
TD 16466
SOLVENT CDCl3
NS 16
DS 2
SWE 3742.515 Hz
FIDRES 0.227287 Hz
AQ 2.1998577 sec
RG 35.9
DM 133.600 usec
DE 6.00 usec
TE 298.2 K
D1 1.0000000 sec
TD0 1

CHANNEL f1
NUC1 1H
P1 13.25 usec
PL1 0 dB
PL1W 15.07131863 W
SFO1 300.1318008 MHz

F2 - Processing parameters
SI 32768
SF 300.1300108 MHz
WDW EM
SSB 0
LB 0.50 Hz
GB 0
PC 1.00




Figure 22: ¹H NMR (19)



ubc_13c(1h) CDCl3 (C:\Bruker\topspin2.1) swithers 17

114.69
116.11
121.33
121.42
127.03
127.12
127.47
127.74
127.94
128.15
128.34
128.67
128.91
133.74
135.85
136.26
136.74
138.15
147.89
154.42
154.88
157.90
158.89

Current Data Parameters
 NAME MFC219-20190529
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20190531
 Time 1.52
 INSTRUM spect
 PROBH 5 mm QNP 1H/1
 PULPROG zgpg30
 TD 27870
 SOLVENT CDCl3
 NS 1000
 DS 4
 SWH 18832.393 Hz
 FIDRES 0.675723 Hz
 AQ 0.73959405 sec
 RG 16384
 DW 26.550 usec
 DE 37.93 usec
 TE 298.5 K
 D1 1.00000000 sec
 D11 0.03000000 sec
 TD0 1

CHANNEL f1
 NUC1 13C
 P1 10.00 usec
 PL1 -1.00 dB
 PL1W 47.43416595 W
 SFO1 75.4755490 MHz

CHANNEL f2
 CPDPRG2 waltz16
 NUC2 1H
 PCPD2 100.00 usec
 PL2 0 dB
 PL2W 17.56 dB
 PL3 16.00 dB
 PL2W 15.07131863 W
 PL3W 0.26432295 W
 PL13W 0.18973666 W
 SFO2 300.1316000 MHz

F2 - Processing parameters
 SI 32768
 SF 75.4677617 MHz
 WDW EM
 SSB 0
 GB 0
 EB 0
 FB 0
 SC 2.00 Hz
 BPC 1.00




Figure 23: ¹³C NMR (19)

13C



Current Data Parameters
NAME MEC288-20190621
EXPNO 2
PROCNO 1

F2 - Acquisition Parameters
Date_ 20190622
Time 8.41
INSTRUM spect
PROBHD 5 mm BBO BB-1H
PULPROG zgpg30
TD 32768
SOLVENT CDCl3
NS 533
DS 2
SWH 25125.629 Hz
FIDRES 0.766773 Hz
AQ 0.6520832 sec
RG 812.7
DQ 19.900 usec
DE 16.00 usec
TE 298.8 K
D1 1.00000000 sec
D11 0.03000000 sec
TD0 1

CHANNEL f1
NUC1 13C
P1 7.45 usec
PL1 -2.00 dB
PL1W 56.92932510 W
SFO1 100.6379188 MHz

CHANNEL f2
CPDPRG12 waltz16
NUC2 1H
PCPD2 90.00 usec
PL2 -2.00 dB
PL2 14.64 dB
PL13 20.00 dB
PL2W 23.88643074 W
PL12W 0.5178710 W
PL13W 0.15071319 W
SFO2 400.1916008 MHz

F2 - Processing parameters
SI 32768
SF 100.6279475 MHz
WDW 0
SSB 0
LB 0
GB 0
PC 1.00 Hz
MC 1.40

175.57
175.16
158.34
158.30
155.09
154.41
137.08
137.00
136.69
136.49
129.10
129.04
128.66
128.60
128.54
128.46
128.32
128.15
128.05
127.72
127.69
114.93
70.06
67.38
67.32
64.10
63.77
47.50
46.55
46.41
46.10
28.77
27.77




Figure 25: ¹³C NMR (21)



Current Data Parameters
 NAME MBC298
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20190716
 Time 8.10
 INSTRUM spect
 PROBHD 5 mm BBO BB-1H
 PULPROG zgpg30
 TD 32768
 SOLVENT CDCl3
 NS 751
 DS 2
 SWH 25125.629 Hz
 FIDRES 0.766773 Hz
 AQ 0.6520832 sec
 RG 812.7
 IQW 19.900 usec
 DE 16.000 usec
 TE 298.8 K
 D1 1.00000000 sec
 D11 0.03000000 sec
 TD0 1

CHANNEL f1
 NUC1 13C
 P1 8.40 usec
 PL1 -2.00 dB
 PL1W 59.71607590 W
 SFO1 100.6379188 MHz

CHANNEL f2
 CPDPRG2 waltz16
 NUC2 1H
 PCPD2 90.00 usec
 PL2 -2.00 dB
 PL2 14.48 dB
 PL3 20.00 dB
 PLZ 23.88643074 W
 PL1W 0.53721893 W
 PL13W 0.15071319 W
 SFO2 400.1916008 MHz

F2 - Processing parameters
 SI 32768
 SF 100.6279602 MHz
 MWDW no
 SSB 0
 GB 0 Hz
 GB 0
 ppmFC 1.40

13C




Figure 29: ¹³C NMR (17)



ubc_13c(1H) CDCl3 (C:\Bruker\topspin2.1) swithers 23

174.66
163.40
159.98
158.98
153.78
151.31
148.66
140.14
137.10
136.23
135.63
128.92
128.76
128.73
128.65
128.18
127.98
127.73
127.38
127.27
127.23
126.88
126.68
123.72
122.48
114.68
114.03
109.53
98.43
93.88
79.23
71.48
71.02
70.97
70.68
69.47
52.88

Current Data Parameters
 NAME MBC162
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20180917
 Time 1.35
 INSTRUM spect
 PROBH 5 mm QNP 1H/1
 PULPROG zgpg30
 TD 27870
 SOLVENT CDCl3
 NS 4000
 DS 4
 SWH 18832.393 Hz
 FIDRES 0.675723 Hz
 AQ 0.73959405 sec
 RG 16384
 DW 26.550 usec
 DE 31.93 usec
 TE 297.7 K
 D1 1.00000000 sec
 D11 0.03000000 sec
 TDO 1

CHANNEL f1
 NUC1 13C
 P1 9.95 usec
 PL1 -1.00 dB
 PL1W 47.43416595 W
 SFO1 75.4755490 MHz

CHANNEL f2
 CPDPRG2 waltz16
 NUC2 1H
 PCPD2 100.00 usec
 PL2 0 dB
 PL3 17.06 dB
 PL13 16.00 dB
 PL2W 15.07131863 W
 PL12W 0.24668980 W
 PL13W 0.18973666 W
 SFO2 300.1316000 MHz

F2 - Processing parameters
 SI 32768
 SF 75.4677412 MHz
 WDW EM
 SSB 0
 GB 0
 LB 0
 GB 0
 MC 2.00 Hz
 PC 1.00




Figure 31: ¹³C NMR (26)



ubc_13c(1H) CDCl3 (C:\Bruker\topspin2.1) swithers 3

173.64
167.93
159.88
158.77
152.83
151.07
148.56
140.20
137.21
136.82
136.47
135.76
128.91
128.74
128.69
128.61
128.54
128.06
127.84
127.53
127.33
126.76
123.74
122.82
119.45
113.95
110.09
98.28
94.02
78.21
77.36
71.71
71.06
70.93
70.63
70.14
52.26
45.06
32.55
29.34
23.53

Current Data Parameters
 NAME MBC166-1
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20180922
 Time 18.08
 INSTRUM spect
 PROBH 5 mm QNP 1H/1
 PULPROG zgpg30
 TD 27870
 SOLVENT CDCl3
 NS 4000
 DS 4
 SWH 18832.393 Hz
 FIDRES 0.67573 Hz
 AQ 0.7395405 sec
 RG 16384
 DW 26.550 usec
 DE 37.93 usec
 TE 299.0 K
 D1 1.00000000 sec
 D11 0.03000000 sec
 TD0 1

CHANNEL f1
 NUC1 13C
 P1 9.95 usec
 PL1 -1.00 dB
 PL1W 47.43416595 W
 SFO1 75.4755490 MHz

CHANNEL f2
 CPDPRG2 waltz16
 NUC2 1H
 PCPD2 100.00 usec
 PL2 0 dB
 PL2 17.86 dB
 PL3 18.00 dB
 PL2W 15.07131863 W
 PL2W 0.24668980 W
 PL3W 0.18973666 W
 SFO2 300.1316000 MHz

F2 - Processing parameters
 SI 32768
 SF 75.4677402 MHz
 EN
 NLW 0
 SSB 0
 LB 2.00 Hz
 GB 0
 MC 1.00




Figure 33: ¹³C NMR (27)




Figure 34: ¹H NMR (30a)



Current Data Parameters
NAME HB57
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20190723
Time_ 4.00 h
INSTRUM spect
PROBHD E116098 0335
PULPROG zgpg30
TD 65536
SOLVENT C6D6
NS 177
DS 2
SWE 24038.461 Hz
FIDRES 0.733596 Hz
AQ 1.3631488 sec
RG 199.6
DM 20.800 usec
DE 6.50 usec
TE 298.2 K
D1 1.0000000 sec
D11 0.0300000 sec
TD0 16
SFO1 100.6404330 MHz
NUC1 13C
P1 9.60 usec
PLW1 68.0000000 W
SFO2 400.2016008 MHz
NUC2 1H
CEDEMG12 waltz16
PCPD2 90.00 usec
PLW2 16.0000000 W
PLW12 0.17902000 W
PLW13 0.09004700 W

F2 - Processing parameters
SI 32768
SF 100.6306246 MHz
WDW no
SSB 0
LB 0 Hz
GB 0
PC 1.40




Figure 35: ¹³C NMR (30a)



Current Data Parameters
NAME HB56
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20190723
Time_ 4.45
INSTRUM spect
PROBHD 5 mm BBO BB-1H
PULPROG zg30
TD 32768
SOLVENT CDCl3
NS 32
DS 2
SWE 5592.841 Hz
FIDRES 0.170680 Hz
AQ 2.9294591 sec
RG 71.8
DM 89.400 usec
DE 6.50 usec
TE 298.1 K
D1 1.00000000 sec
TDO 1

CHANNEL f1
NUC1 1H
P1 13.50 usec
PL -2.00 dB
PL1W 23.88643074 W
SFO1 400.1926012 MHz

F2 - Processing parameters
SI 32768
SF 400.1909738 MHz
WDW no
SSB 0
LB 0 Hz
GB 0
PC 1.00

¹H




Figure 36: ¹H NMR (30b)

13C




Figure 37: ¹³C NMR (30b)

ubc_1H MeOD (C:\Bruker\topspin2.1) swithers 42



Current Data Parameters
NAME MBC391S
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20190724
Time 12.02
INSTRUM spect
PROBHD 5 mm QNP 1H/1
PULPROG zg30
TD 16466
SOLVENT MeOD
NS 16
DS 2
SWH 3742.515 Hz
FIDRES 0.227287 Hz
AQ 2.1998577 sec
RG 181
DW 133.600 usec
DE 6.00 usec
TE 297.9 K
D1 1.0000000 sec
TDO 1

===== CHANNEL f1 =====
NUC1 1H
P1 13.25 usec
PL1 0 dB
PL1W 15.07131863 W
SFO1 300.1318008 MHz

F2 - Processing parameters
SI 32768
SF 300.1300076 MHz
WDW EM
SSB 0
LB 0.50 Hz
GB 0
PC 1.00




Figure 38: ¹H NMR (34a)





Figure 39: ¹³C NMR (34 a)






Figure 41: ¹³C NMR (34b)


Kinetic Analysis of Inhibitors

Human pancreatic alpha-amylase (HPA) was expressed in *Pichia pastoris* and purified as described in some detail previously². 2-Chloro-4-nitrophenyl α -maltotrioside (CNPG3) was purchased from Sekisui Enzymes. Incubation of this substrate with HPA leads to the release of 2-chloro-nitrophenol, and this was monitored by measuring the absorbance of the reaction solutions at 400 nm.

The assays were performed with either a Varian Cary 4000 UV/Vis spectrophotometer or a BioTek Synergy H1 plate reader. After the start of the reactions by addition of the substrates, the absorbance of the solutions were monitored over 5 minutes to measure the initial reaction rate. Reactions were run at 30°C in 50 mM sodium phosphate including 100 mM sodium chloride (pH 7.0). The assays were performed using two to five different [CNPG3] (2 mM and 4 mM; 2 mM, 4 mM, and 6 mM; 2 mM, 3 mM, 4 mM, 6 mM and 8 mM) for each range of inhibitor concentrations. Inhibitor concentrations generally ranging from 1/5 to 5x K_I were used. For each reaction, HPA was incubated with varying [I] at 30°C for at least 1 minute prior to addition of CNPG3 substrates. The resulting initial rate data were fit to a competitive inhibition model using nonlinear regression analysis, as performed by the GraFit 7.0 program to provide a value for K_I . Dixon and Lineweaver-Burke plots of each data set validated the use of a competitive inhibition model.

Compound	K_I (μ M)
13	0.29 \pm 0.02
14	0.40 \pm 0.02
17	0.10 \pm 0.01
30a	0.07 \pm 0.03
30b	0.20 \pm 0.06
36a	0.34 \pm 0.02
36b	1.2 \pm 0.18
38a	1.56 \pm 0.25
47a	11 \pm 1.5
48a	0.76 \pm 0.08
49a	\sim 50 \pm 12
Mini-MbA	0.39 \pm 0.05

Dixon Plot Competitive Fit



Parameter	Value	Std. Error
Vmax	0.1424	0.0046
Km	3184.0156	246.3102
Ki	0.2910	0.0206

Figure 42: Dixon plot for 13. All concentrations in μM





Figure 43: Dixon plot for 14. All concentrations in μM .


Dixon Plot Competitive Fit



Parameter	Value	Std. Error
Vmax	0.3061	0.0182
Km	4214.9682	510.4367
Ki	0.0985	0.0086

Figure 44: Dixon plot for **17**. All concentrations in μM .


Dixon Plot Competitive Fit



Parameter	Value	Std. Error
Vmax	0.1919	0.0496
Km	4345.2807	2277.9619
Ki	0.0705	0.0256

Figure 45: Dixon plot for **30a**. All concentrations in μM .


Dixon Plot Competitive Fit



Parameter	Value	Std. Error
Vmax	0.2078	0.0551
Km	5977.6560	2782.7603
Ki	0.1981	0.0587

Figure 46: Dixon plot for **30b**. All concentrations in μM .


Dixon Plot Competitive Fit



Parameter	Value	Std. Error
Vmax	0.1415	0.0073
Km	5496.1706	598.3113
Ki	0.3368	0.0230

Figure 47: Dixon plot for **36a**. All concentrations in μM .


Dixon Plot Competitive Fit



Parameter	Value	Std. Error
Vmax	0.2503	0.0266
Km	4166.1719	908.1948
Ki	1.2109	0.1806

Figure 48: Dixon Plot for **36b**. All concentrations in uM.


Dixon Plot Competitive Fit



Parameter	Value	Std. Error
Vmax	17.9529	1.5178
Km	3274.0189	634.0382
Ki	1.5575	0.2458

Figure 49: Dixon plot for **38a**. All concentrations in μM

Dixon Plot Competitive Fit



Parameter	Value	Std. Error
Vmax	78.2885	6.3829
Km	5703.8952	831.2312
Ki	10.5456	1.4661

Figure 50: Dixon plot for 47a All concentrations in uM.

Dixon Plot Competitive Fit





Figure 51: Dixon plot for **48a**. All concentrations in μM .


Dixon Plot Competitive Fit



Parameter	Value	Std. Error
Vmax	53.2159	1.7681
Km	3858.5909	271.3948
Ki	52.2972	12.2007

Figure 52: Dixon plot for **49a**. All concentrations in μM .

Dixon Plot Competitive Fit



Parameter	Value	Std. Error
Vmax	19.2595	1.6741
Km	3185.4885	644.8151
Ki	0.3839	0.0554

Figure 53: Dixon plot for *mini MbA*. All concentrations in μM .

- (1) Smith, R. M.; Weiner, D. P.; Chaturvedi, N. C.; Thimblin, M. D.; Raymond, S. J.; Hansen, D. E. *Bioorganic Chemistry* **1995**, *23*, 397.
- (2) Tysoe, C. R.; Caner, S.; Calvert, M. B.; Win-Mason, A.; Brayer, G. D.; Withers, S. G. *Chem Sci* **2019**, *10*, 11073.
- (3) Villaume, S. A.; Fu, J.; N'Go, I.; Liang, H.; Lou, H.; Kremer, L.; Pan, W.; Vincent, S. *P. Chemistry – A European Journal* **2017**, *23*, 10423.
- (4) Ban, H.; Nagano, M.; Gavriluk, J.; Hakamata, W.; Inokuma, T.; Barbas, C. F. *Bioconjugate Chemistry* **2013**, *24*, 520.